High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Metastatic Rhabdomyosarcoma—A Systematic Review
2011

High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Metastatic Rhabdomyosarcoma—A Systematic Review

Sample size: 287 publication Evidence: low

Author Information

Author(s): Frank Peinemann, Nicolau Kröger, Carmen Bartel, Ulrich Grouven, Max Pittler, Rudolf Erttmann, Michael Kulig

Primary Institution: Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany

Hypothesis

Does high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation provide additional benefit or harm compared to standard chemotherapy in patients with metastatic rhabdomyosarcoma?

Conclusion

High-dose chemotherapy followed by autologous HSCT in patients with metastatic rhabdomyosarcoma remains an experimental treatment and is not justifiable outside of controlled trials.

Supporting Evidence

  • 40 studies with 287 transplant patients were included in the assessment.
  • The 3-year overall survival ranged from 22% to 53% in the transplant groups vs. 18% to 55% in the control groups.
  • Meta-analysis showed no significant difference in overall survival between treatments.
  • The risk of bias was high in all studies due to methodological flaws.

Takeaway

This study looked at whether a stronger cancer treatment helps kids with a specific type of cancer called rhabdomyosarcoma. It found that the stronger treatment doesn't seem to work better than the usual one.

Methodology

Systematic literature searches were performed in MEDLINE, EMBASE, and The Cochrane Library, including randomized and non-randomized controlled trials, case series, and case reports.

Potential Biases

High risk of bias due to flaws in study design and patient assignment.

Limitations

The risk of bias was high in all studies due to methodological flaws, and there was a lack of controlled trials.

Participant Demographics

Patients included were aged 0 to 32 years, with a focus on those with metastatic rhabdomyosarcoma.

Statistical Information

P-Value

p=0.001 for one controlled trial showing significant difference in survival.

Confidence Interval

95% CI: 15 to 43 for pooled individual data.

Digital Object Identifier (DOI)

10.1371/journal.pone.0017127

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication